Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer A Population-Based Cohort Study

Study of 17,922 women with breast cancer reported use of aromatase inhibitors was associated with increased risks of heart failure and cardiovascular mortality and trends toward increased risks of myocardial infarction and ischaemic stroke compared with the use of tamoxifen.

SPS commentary:

The use of aromatase inhibitors was associated with a significantly increased risk of heart failure (incidence rate 5.4 vs 1.8 per 1000 person-years; HR 1.86 [95% CI 1.14–3.03]) and cardiovascular mortality (incidence rate 9.5 versus 4.7 per 1000 person-years; HR 1.50 [1.11–2.04]) compared with the use of tamoxifen.

Circulation